Loading patent…
AssigneeBiogen MA Inc.
InventorsMichael Joseph Palte, Brian T. Hopkins, Matthew P. Scaramozza, Michael Christian Mingueneau, Alex Pellerin, Chelsea R. Parker Harp, Catherine Barbey
Estimating the term…
The present disclosure provides combination therapies for treating an autoimmune disease in a subject in need thereof. The methods comprise administering to the subject an effective amount of a BTK inhibitor in combination with an effective amount of a fumaric acid ester (FAE). The autoimmune disease can be treated include, for example, multiple sclerosis (MS), lupus, rheumatoid arthritis (RA), Pemphigus Vugaris (PV), neuromyelitis optica (NMO), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), anti-NMDA receptor encephalitis, or Sjogren's disease.
A method of treating an autoimmune disease in a subject in need thereof comprising administering to the subject an effective amount of a BTK inhibitor and an effective amount of a fumaric acid ester (FAE), wherein the BTK inhibitor is BIIB-091 and the FAE is dimethyl fumarate (DMF) or diroximel fumarate (DRF);
Dependencies are inferred from the claim text.